Davunetide Alternatives

Selank is a synthetic seven-amino-acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) built from the natural immune peptide tuftsin, with a small chemical tweak to make it last longer in the body. It was developed in Russia as an anti-anxiety and nootropic agent and is approved there for generalized anxiety disorder, but it has no FDA or EMA approval and almost no Western clinical data. The pitch is calm and focus without the sedation, dependence, or withdrawal that come with benzodiazepines.

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed in Russia in the 1980s as an analog of the ACTH(4-10) fragment, with a Pro-Gly-Pro tail added to resist breakdown. It is researched and used as a neuroprotective and nootropic agent, typically intranasally, and keeps the cognitive and neurotrophic effects of the ACTH fragment without the parent hormone's cortisol-raising activity. It is used clinically and registered in Russia (including for ischemic stroke and cognitive disorders) but is not approved by the FDA or EMA, and Western evidence is limited.

Cerebrolysin is not a single peptide but a mixture: a preparation of small peptides and free amino acids made by enzymatically breaking down purified porcine (pig) brain protein, manufactured by EVER Neuro Pharma in Austria. It is given by injection and is approved as a prescription drug in dozens of countries for stroke, traumatic brain injury, and dementia, but it is not FDA-approved in the United States. Despite decades of use abroad, the human evidence remains genuinely contested.

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small synthetic peptide built from angiotensin IV, engineered at Washington State University to be orally active and to cross into the brain. The pitch is bold: it is studied as a procognitive compound that may rebuild synaptic connections, and lab claims of extreme potency made it a darling of the nootropic underground. The reality check: every supporting study is in cells or rodents, there are zero human clinical trials, and in April 2025 the journal retracted two of the key papers behind its proposed mechanism (2012 and 2014) after a university investigation.

P21 (also written P021) is a small synthetic peptide reverse-engineered from the most active region of ciliary neurotrophic factor (CNTF), with an adamantane group bolted on to help it survive in the body and reach the brain. It is studied as a neurogenic and neurotrophic compound for Alzheimer's disease and other memory disorders, with the appeal of getting CNTF-like benefits in a small, orally available molecule. The honest status: it looks genuinely promising in mouse models, but the entire evidence base comes from a single research group and there are no human trials.

GB-115 is a synthetic dipeptide anxiolytic developed in Russia, chemically the amide of N-phenylhexanoyl-glycyl-L-tryptophan and described as a retro-analogue of cholecystokinin-4. Rather than acting like a benzodiazepine, it blocks cholecystokinin receptors, a different anti-anxiety route. It has been studied in animals and in a small pilot human study, but it is not an approved or widely available medication.

ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide carved from the tissue-protective region of erythropoietin (EPO), engineered to calm inflammation and repair nerves without thickening the blood the way EPO does. It has been tested in real Phase 2 human trials, mainly for sarcoidosis-related small fiber neuropathy and diabetic neuropathy, and holds FDA orphan drug status, but it was never approved and development largely stalled. So: genuine clinical data, promising signals, no finish line.

Normoftal is an obscure Russian eye supplement from the Khavinson 'peptide bioregulator' tradition, sold as short peptides meant to support the retina. Be clear-eyed about this one: it is marketed as a dietary supplement, not an approved drug, and the evidence behind it is thin and comes almost entirely from one research lineage. We keep the claims minimal on purpose.